Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study
Purpose To investigate the efficacy and safety of intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Design Prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods One…